Allarity Therapeutics Raises $20M, Gains FDA Fast Track for Ovarian Cancer Candidate
Allarity Therapeutics closed 2025 with $14.7 million in cash, extending its runway into mid-2028 through disciplined cost management. It won FDA Fast Track designation for stenoparib in advanced ovarian cancer, launched a VA-funded Phase 2 small cell lung cancer combination trial and secured $20 million in debt financing.
1. Full Year Financial Results
Allarity Therapeutics ended 2025 with $14.7 million in cash, reduced operating cash burn and extended its cash runway into mid-2028 after disciplined cost management.
2. FDA Fast Track Designation and Clinical Progress
The FDA Fast Track designation for stenoparib in advanced ovarian cancer enables more frequent regulatory engagement, while updated Phase 2 data show some patients on monotherapy for nearly 30 months.
3. Small Cell Lung Cancer Trial and DRP Platform Licensing
In early 2026 Allarity launched a VA-funded Phase 2 trial of stenoparib plus temozolomide in recurrent small cell lung cancer across 11 VA centers, and began commercial licensing of its DRP companion diagnostic with expanded Denmark lab services.
4. Leadership and Financing
Jeff Ervin joined as Chief Financial Officer and Jesper Høiland was appointed to the board, and the company secured $20 million in non-convertible debt financing to accelerate development toward pivotal trials.